Medicines Co. buys Curacyte subsidiary

The Medicines Company is buying Curacyte subsidiary Curacyte Discovery for €14.5 million up front. Curacyte Discovery is developing a serine protease inhibitor in the area of hemostasis and anti-coagulation. Its lead candidate, CU-2010, a treatment for preventing surgical blood loss, is expected to enter Phase I trials by the end of this year. The Medicines Company gains CU-2010 as part of the deal, and Curacyte could receive an additional payment of €10.5 million if the drug proceeds to Phase II clinical development--Curacyte could also earn commercial milestone and royalty payments.

"The transaction will help the parent company, Curacyte, to focus on fully developing its key product, hemoximer, in a pivotal Phase III study in distributive shock," said Dr. Helmut Giersiefen, Curacyte's CEO.

 - here's the release

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.